156 related articles for article (PubMed ID: 29490959)
1. Design of a phase IV randomised, double-blind, placebo-controlled trial assessing the Im
Emery P; Burmester GR; Naredo E; Zhou Y; Hojnik M; Conaghan PG
BMJ Open; 2018 Feb; 8(2):e019007. PubMed ID: 29490959
[TBL] [Abstract][Full Text] [Related]
2. Dosage reduction and discontinuation of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: protocol for a pragmatic, randomised controlled trial (the BIOlogical Dose OPTimisation (BIODOPT) trial).
Uhrenholt L; Schlemmer A; Hauge EM; Christensen R; Dreyer L; Suarez-Almazor ME; Kristensen S
BMJ Open; 2019 Jul; 9(7):e028517. PubMed ID: 31292181
[TBL] [Abstract][Full Text] [Related]
3. Effects of tapering conventional synthetic disease-modifying antirheumatic drugs to drug-free remission versus stable treatment in rheumatoid arthritis (ARCTIC REWIND): 3-year results from an open-label, randomised controlled, non-inferiority trial.
Kjørholt KE; Sundlisæter NP; Aga AB; Sexton J; Olsen IC; Fremstad H; Spada C; Madland TM; Høili CA; Bakland G; Lexberg Å; Hansen IJW; Hansen IM; Haukeland H; Ljoså MA; Moholt E; Uhlig T; Kvien TK; Solomon DH; van der Heijde D; Haavardsholm EA; Lillegraven S
Lancet Rheumatol; 2024 May; 6(5):e268-e278. PubMed ID: 38583450
[TBL] [Abstract][Full Text] [Related]
4. Effect of tapered versus stable treatment with tumour necrosis factor inhibitors on disease flares in patients with rheumatoid arthritis in remission: a randomised, open label, non-inferiority trial.
Lillegraven S; Paulshus Sundlisæter N; Aga AB; Sexton J; Olsen IC; Lexberg ÅS; Madland TM; Fremstad H; Høili CA; Bakland G; Spada C; Haukeland H; Hansen IM; Moholt E; Uhlig T; Solomon DH; van der Heijde D; Kvien TK; Haavardsholm EA
Ann Rheum Dis; 2023 Nov; 82(11):1394-1403. PubMed ID: 37607809
[TBL] [Abstract][Full Text] [Related]
5. Arthritis prevention in the pre-clinical phase of RA with abatacept (the APIPPRA study): a multi-centre, randomised, double-blind, parallel-group, placebo-controlled clinical trial protocol.
Al-Laith M; Jasenecova M; Abraham S; Bosworth A; Bruce IN; Buckley CD; Ciurtin C; D'Agostino MA; Emery P; Gaston H; Isaacs JD; Filer A; Fisher BA; Huizinga TWJ; Ho P; Jacklin C; Lempp H; McInnes IB; Pratt AG; Östor A; Raza K; Taylor PC; van Schaardenburg D; Shivapatham D; Wright AJ; Vasconcelos JC; Kelly J; Murphy C; Prevost AT; Cope AP
Trials; 2019 Jul; 20(1):429. PubMed ID: 31307535
[TBL] [Abstract][Full Text] [Related]
6. Three-month tapering and discontinuation of long- term, low-dose glucocorticoids in senior patients with rheumatoid arthritis is feasible and safe: placebo-controlled double blind tapering after the GLORIA trial.
Almayali AAH; Boers M; Hartman L; Opris D; Bos R; Kok MR; Da Silva JA; Griep E; Klaasen R; Allaart CF; Baudoin P; Raterman HG; Szekanecz Z; Buttgereit F; Masaryk P; Lems W; Smulders Y; Cutolo M; Ter Wee MM
Ann Rheum Dis; 2023 Oct; 82(10):1307-1314. PubMed ID: 37541762
[TBL] [Abstract][Full Text] [Related]
7. A real-world 2-year prospective study of medication tapering in patients with well-controlled rheumatoid arthritis within the rheumatoid arthritis medication tapering (RHEUMTAP) cohort.
Tageldin M; Wilson N; Yin Y; Sharma TS
Rheumatology (Oxford); 2023 Oct; 62(Suppl_4):iv8-iv13. PubMed ID: 37855679
[TBL] [Abstract][Full Text] [Related]
8. Validation and predictive capacity of a Dutch version of the FLARE-RA questionnaire within the context of a TNFi-tapering trial.
Doumen M; Bertrand D; Pazmino S; De Cock D; Stouten V; Joly J; de Wergifosse I; Moeyersoons A; Westhovens R; Verschueren P
Clin Rheumatol; 2023 Jan; 42(1):39-45. PubMed ID: 35943667
[TBL] [Abstract][Full Text] [Related]
9. Treatment tapering and stopping in patients with rheumatoid arthritis in stable remission (RETRO): a multicentre, randomised, controlled, open-label, phase 3 trial.
Tascilar K; Hagen M; Kleyer A; Simon D; Reiser M; Hueber AJ; Manger B; Englbrecht M; Finzel S; Tony HP; Schuch F; Kleinert S; Wendler J; Ronneberger M; Figueiredo CP; Cobra JF; Feuchtenberger M; Fleck M; Manger K; Ochs W; Schmitt-Haendle M; Lorenz HM; Nuesslein H; Alten R; Kruger K; Henes J; Schett G; Rech J
Lancet Rheumatol; 2021 Nov; 3(11):e767-e777. PubMed ID: 38297524
[TBL] [Abstract][Full Text] [Related]
10. Intensive intervention can lead to a treatment holiday from biological DMARDs in patients with rheumatoid arthritis.
Tanaka Y; Hirata S
Drugs; 2014 Dec; 74(18):2129-39. PubMed ID: 25389048
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of curcumin in maintaining remission during disease-modifying antirheumatic drug withdrawal in rheumatoid arthritis at 52 weeks: a phase III double-blind, randomized placebo-controlled trial.
Bhat SS; Ahmed S; Reji R; Mehta P; Paul A; Mohanan M; Babu S; Vinayak B; Vijayan A; Nalianda KK; Joseph S; Narayanan K; Padmaja R; Alex G; Shenoy P
Rheumatol Int; 2023 Dec; 43(12):2193-2200. PubMed ID: 37650921
[TBL] [Abstract][Full Text] [Related]
12. Impact of tapering targeted therapies (bDMARDs or JAKis) on the risk of serious infections and adverse events of special interest in patients with rheumatoid arthritis or spondyloarthritis: a systematic analysis of the literature and meta-analysis.
Vinson D; Molet-Benhamou L; Degboé Y; den Broeder A; Ibrahim F; Pontes C; Westhovens R; Závada J; Pham T; Barnetche T; Constantin A; Ruyssen-Witrand A
Arthritis Res Ther; 2020 Apr; 22(1):97. PubMed ID: 32349791
[TBL] [Abstract][Full Text] [Related]
13. Continuing versus tapering low-dose glucocorticoids in patients with rheumatoid arthritis and systemic lupus erythematosus in states of low disease activity or remission: A systematic review and meta-analysis of randomised trials.
Palmowski A; Pankow A; Terziyska K; Nielsen SM; Christensen R; Bliddal H; Boyadzhieva Z; Buttgereit F
Semin Arthritis Rheum; 2024 Feb; 64():152349. PubMed ID: 38100900
[TBL] [Abstract][Full Text] [Related]
14. Ability to predict rheumatoid arthritis relapse after tumour necrosis factor inhibitor tapering by the Multi-Biomarker Disease Activity Score: a post-hoc analysis of the STRASS trial.
Moysidou GS; Marotte H; Kossi S; Tubach F; Hajage D; Fautrel B
Clin Exp Rheumatol; 2023 Sep; 41(9):1831-1837. PubMed ID: 37497730
[TBL] [Abstract][Full Text] [Related]
15. The Gap in Knowledge about Tapering Targeted Therapy being used as Monotherapy in Rheumatoid Arthritis: A Systematic Review.
Meng CF; Rajesh DA; Jannat-Khat DP; Jivanelli B; Bykerk V
Curr Rheumatol Rev; 2024; 20(1):46-56. PubMed ID: 37641998
[TBL] [Abstract][Full Text] [Related]
16. Cost-utility analysis of tapering strategies of biologicals in rheumatoid arthritis patients in the Netherlands.
van Esveld L; Cox JM; Kuijper TM; Bosch TM; Weel-Koenders AE
Ann Rheum Dis; 2023 Oct; 82(10):1296-1306. PubMed ID: 37423648
[TBL] [Abstract][Full Text] [Related]
17. Safety and patient response as indicated by biomarker changes to binding immunoglobulin protein in the phase I/IIA RAGULA clinical trial in rheumatoid arthritis.
Kirkham B; Chaabo K; Hall C; Garrood T; Mant T; Allen E; Vincent A; Vasconcelos JC; Prevost AT; Panayi GS; Corrigall VM
Rheumatology (Oxford); 2016 Nov; 55(11):1993-2000. PubMed ID: 27498355
[TBL] [Abstract][Full Text] [Related]
18. In RA in remission for >1 y, tapering TNFi to discontinuation did not meet noninferiority criteria compared with stable TNFi for disease flare at 12 mo.
Lafita FR
Ann Intern Med; 2023 Dec; 176(12):JC139. PubMed ID: 38048575
[TBL] [Abstract][Full Text] [Related]
19. Lessons learnt from a discontinued randomised controlled trial: adalimumab injection compared with placebo for patients receiving physiotherapy treatment for sciatica (Subcutaneous Injection of Adalimumab Trial compared with Control: SCIATiC).
Williams NH; Jenkins A; Goulden N; Hoare Z; Hughes DA; Wood E; Foster NE; Walsh D; Carnes D; Sparkes V; Hay EM; Isaacs J; Konstantinou K; Morrissey D; Karppinen J; Genevay S; Wilkinson C
Trials; 2018 Jul; 19(1):408. PubMed ID: 30064491
[TBL] [Abstract][Full Text] [Related]
20. Treatment patterns of individualized real-life tapering approaches based on shared decision-making in rheumatoid arthritis.
Birkner B; Rech J; Edelmann E; Verheyen F; Schett G; Stargardt T
Z Rheumatol; 2024 Mar; 83(2):142-150. PubMed ID: 37351593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
